Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has issued an update.
Qiagen has disclosed a managers’ transaction involving Thierry Bernard, a member of its managing body, who received 7,650 Performance Stock Units granted in 2016 that vested on February 15, 2026. Following net share settlement to cover taxes and related costs, Bernard ultimately obtained 3,856 common shares, in a transaction executed outside a trading venue and linked to the company’s share-based compensation program.
The release underscores Qiagen’s ongoing use of equity incentives to align management interests with shareholders, a common practice among listed life sciences companies. While the transaction is not quantifiable in aggregate terms within the disclosure, it reflects routine governance and transparency obligations under market abuse regulations and signals continued reliance on performance-based stock awards in the company’s executive remuneration structure.
The most recent analyst rating on (QGEN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies used in molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed on multiple European exchanges as well as on the NYSE and Swiss markets, giving it broad access to international capital and a diverse investor base.
Average Trading Volume: 2,029,889
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.42B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.